Zalles Nicole, Williamson Sean R
Department of Pathology and Laboratory Medicine, Cleveland Clinic, 9500 Euclid Avenue L25, Cleveland, OH 44195, USA.
Department of Pathology and Laboratory Medicine, Cleveland Clinic, 9500 Euclid Avenue L25, Cleveland, OH 44195, USA.
Surg Pathol Clin. 2025 Mar;18(1):133-155. doi: 10.1016/j.path.2024.08.011. Epub 2024 Oct 9.
Diagnostic challenges remain among the common renal cell carcinoma (RCC) subtypes. High-grade clear cell RCC may have deceptive patterns, for example BAP1-deficient tumors. Subtyping type 1 and 2 papillary RCC is no longer recommended, as former type 2 tumors may now be contain other diagnostic entities, such as FH-deficient RCC, MITF family RCC, or others. Clear cell papillary tumor is no longer considered carcinoma due to its highly favorable behavior. However, imperfect examples are best considered clear cell RCC. Oncocytic renal neoplasm of low malignant potential has been proposed as a borderline category in the absence of overt malignant features.
常见肾细胞癌（RCC）亚型的诊断仍存在挑战。高级别透明细胞肾细胞癌可能有欺骗性表现，例如BAP1缺陷型肿瘤。不再推荐对1型和2型乳头状肾细胞癌进行亚型分类，因为以前的2型肿瘤现在可能包含其他诊断实体，如FH缺陷型肾细胞癌、MITF家族性肾细胞癌或其他类型。透明细胞乳头状肿瘤因其行为高度良性，不再被视为癌。然而，不典型的病例最好视为透明细胞肾细胞癌。在没有明显恶性特征的情况下，低恶性潜能的嗜酸细胞性肾肿瘤被提议作为一个临界类别。
